Search company, investor...
Search

Predict your next investment

Thermo Fisher Scientific company logo
Corporation
HEALTHCARE | Biotechnology
thermofisher.com

See what CB Insights has to offer

Investments

5

Portfolio Exits

7

Partners & Customers

10

About Thermo Fisher Scientific

Thermo Fisher Scientific provides a broad range of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics applications. Clients include pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies. The company's portfolio of products includes technologies for mass spectrometry, elemental analysis, molecular spectroscopy, sample preparation, informatics, fine and high-purity chemistry production, cell culture, RNA interference analysis, and immunodiagnostic testing.

Thermo Fisher Scientific Headquarters Location

168 Third Avenue

Waltham, Massachusetts, 02451,

United States

781 622 1000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Thermo Fisher Scientific

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Thermo Fisher Scientific in 4 Expert Collections, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

C

Cancer

105 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

M

Medical Devices

3,468 items

https://mdic.org/membership/our-members/

H

Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

Thermo Fisher Scientific Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Thermo Fisher Scientific Rank

Research containing Thermo Fisher Scientific

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Thermo Fisher Scientific in 1 CB Insights research brief, most recently on Mar 4, 2020.

Latest Thermo Fisher Scientific News

Molecular Biology Enzymes, Kits & Reagents Market worth USD 22,000 Mn by 2026 at a CAGR of 15.8%

Sep 28, 2022

Search jobs 28-Sep-2022 Molecular Biology Enzymes, Kits & Reagents Market worth USD 22,000 Mn by 2026 at a CAGR of 15.8% Future Market Insights’ recently compiled report offers prospects of the global  molecular biology enzymes, kits & reagents market growth  for the period between 2017 and 2026. The report projects the market to register a splendid growth through 2026. Sales of molecular biology enzymes, kits & reagents worldwide are poised to exceed US$ 22,000 Mn in revenues by 2026-end. Technological Advancements Leading to Enhanced Efficiency & Greater Precision of Molecular Biology Enzymes, Kits & Reagents Many technological advancements are been made by the molecular biology enzymes, kits & reagents manufacturers, who dedicate their focus toward developing advanced products in a bid to enhance their product portfolio. The advanced products facilitate the research processes with offerings such as enhanced efficiency and greater precision. One of the greatest examples of this is SMART Digest Kit developed by Thermo Fisher Scientific, Inc., designed particularly for the biopharmaceutical & proteomic applications. This kit enables the generation of data of high quality, meanwhile curtailing time needed for preparation of samples. Adoption of molecular biology enzymes, kits & reagents will further be propelled by huge investments made in the research & development by pharmaceutical & biotechnology industries coupled with the provision of several reimbursements for molecular diagnostics. A significant increase in the genetic disorders’ prevalence has been witnessed since the recent past, thereby driving adoption of molecular diagnostics. The processes of molecular diagnostics including epigenetics and polymerase chain reaction (PCR) require molecular biology enzymes, kits & reagents as, which form an integral part of these processes. Mounting cases of genetic disorders in light of growing geriatric population will significantly fuel demand for molecular biology enzymes, kits & reagents in the near future. Genetic data of individuals is considered highly confidential, and sharing this data is strictly prohibited. Genome sequencing aids identifying & treating a wide variety of diseases. However, there is lack of tools that are effective for securing the genetic information of individuals, and the information ends up being stored in cloud databases, which further poses threats regarding data thefts. The absence of effective technology to store genetic information is anticipated to negatively influence demand for molecular biology enzymes, kits & reagents. Request Sample PDF Brochure: Key Research Findings from the Report Although sequencing is expected to prevail as the largest application of molecular biology enzymes, kits & reagents in terms of revenues, synthetic biology is anticipated to persist as the fastest expanding application segment in the market. Cloning application segment will also exhibit an impressive expansion, and will account for the second largest revenue share of the market during the forecast period. Academic and research institutes are expected to register fastest expansion in the market through 2026, based on end-users. However, revenues from this end-user segment will remain comparatively lower than other end-user segments included in the report. Revenues from sales of molecular biology enzymes, kits & reagents for use in pharmaceutical and biotechnology companies are expected to account for the largest market share during 2017 to 2026. Kits & reagents will prevail as top-selling and fast-selling product in the market. Between modifying enzymes and restriction enzymes, the latter will exhibit a relatively faster sales expansion whereas the former will account for a larger market revenue share through 2026. North America is anticipated to remain the most remunerative market for molecular biology enzymes, kits & reagents, followed by Asia-Pacific excluding Japan (APEJ). Prominent companies in the global molecular biology enzymes, kits & reagents market are implementing strategies including manufacturing capacity & geographic expansion. Manufacturers are also concentrating on new product launches for enhancing their shares in this increasingly competitive market. The report has listed key players supporting the market growth, which include Thermo Fisher Scientific Inc., Illumina, Inc., Roche Holdings, Inc., Takara Bio Inc., Jena Bioscience GmbH, Merck & Co Company, Qiagen N.V., Agilent Technologies, Inc., KRISHGEN BioSystems, and Promega Corporation. Browse Full Report: ABOUT FUTURE MARKET INSIGHTS, INC. Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through  MarketNgage , the market intelligence engine from Future Market Insights. Sign Up  for a 7 day free trial! Contact:

Thermo Fisher Scientific Investments

5 Investments

Thermo Fisher Scientific has made 5 investments. Their latest investment was in Ionpath as part of their Corporate Minority on May 5, 2022.

CBI Logo

Thermo Fisher Scientific Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/11/2022

Corporate Minority

Ionpath

Yes

2

2/24/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

10/30/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/19/2019

Corporate Minority

Subscribe to see more

Subscribe to see more

10

3/11/2004

Series A

Subscribe to see more

$99M

Subscribe to see more

0

Date

5/11/2022

2/24/2021

10/30/2019

2/19/2019

3/11/2004

Round

Corporate Minority

Series B

Series A

Corporate Minority

Series A

Company

Ionpath

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

10

0

Thermo Fisher Scientific Portfolio Exits

7 Portfolio Exits

Thermo Fisher Scientific has 7 portfolio exits. Their latest portfolio exit was Arranta Bio on February 18, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/18/2022

Acquired

$99M

3

6/29/2019

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

1/28/2019

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

7/19/2017

Acquired - III

Subscribe to see more

$99M

Subscribe to see more

10

8/30/2013

Acquired - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/18/2022

6/29/2019

1/28/2019

7/19/2017

8/30/2013

Exit

Acquired

Divestiture

Divestiture

Acquired - III

Acquired - II

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Thermo Fisher Scientific Acquisitions

45 Acquisitions

Thermo Fisher Scientific acquired 45 companies. Their latest acquisition was MAX Analytical Technologies on March 27, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/27/2022

$99M

Acquired

1

1/5/2022

$99M

Acquired

8

12/8/2021

Other

$99M

$71.05M

Acq - P2P

16

11/1/2021

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

10/4/2021

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

3/27/2022

1/5/2022

12/8/2021

11/1/2021

10/4/2021

Investment Stage

Other

Series B

Series A

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$71.05M

$99M

$99M

Note

Acquired

Acquired

Acq - P2P

Subscribe to see more

Subscribe to see more

Sources

1

8

16

10

10

Thermo Fisher Scientific Partners & Customers

10 Partners and customers

Thermo Fisher Scientific has 10 strategic partners and customers. Thermo Fisher Scientific recently partnered with UgenTec on September 9, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

9/15/2022

Partner

Belgium

1

9/13/2022

Partner

Taiwan

Thermo Fisher Scientific Collaborates with Taiwan Precision Medicine Initiative to Genotype 1 Million People in Taiwan

CARLSBAD , Calif. -- -- Thermo Fisher Scientific Inc. partners with the Taiwan Precision Medicine Initiative to advance the next phase of the large-scale predictive genomics study and support its goal of genotyping 1 million people in Taiwan .

2

6/27/2022

Partner

India

United Way Bengaluru and Thermo Fisher join hands to build a 30-bed modular hospital at Tobu Block in Mon District of Nagaland

Reckoning the need to strengthen health infrastructure in the block , United Way and CSR partner Thermo Fisher Scientific Inc. came forward and set up a 30-bed modular facility , type C ambulance , dental and paediatric medical equipment as an extension to the existing community health center .

1

6/14/2022

Partner

Israel

Subscribe to see more

Subscribe to see more

10

6/8/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

9/15/2022

9/13/2022

6/27/2022

6/14/2022

6/8/2022

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

Belgium

Taiwan

India

Israel

United States

News Snippet

Thermo Fisher Scientific Collaborates with Taiwan Precision Medicine Initiative to Genotype 1 Million People in Taiwan

CARLSBAD , Calif. -- -- Thermo Fisher Scientific Inc. partners with the Taiwan Precision Medicine Initiative to advance the next phase of the large-scale predictive genomics study and support its goal of genotyping 1 million people in Taiwan .

United Way Bengaluru and Thermo Fisher join hands to build a 30-bed modular hospital at Tobu Block in Mon District of Nagaland

Reckoning the need to strengthen health infrastructure in the block , United Way and CSR partner Thermo Fisher Scientific Inc. came forward and set up a 30-bed modular facility , type C ambulance , dental and paediatric medical equipment as an extension to the existing community health center .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

1

10

10

Thermo Fisher Scientific Team

68 Team Members

Thermo Fisher Scientific has 68 team members, including current Chief Executive Officer, President, Marc Casper.

Name

Work History

Title

Status

Marc Casper

Chief Executive Officer, President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Marc Casper

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer, President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

You May Also Like

Cepheid Logo
Cepheid

Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial, and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification, and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. Cepheid previously traded under the ticker NASDAQ: CPHD.

Baebies Logo
Baebies

Baebies developed a nimble bioassay automation platform to rapidly perform multiplex enzymatic assays and other tests. The company licensed its core technology, digital microfluidics, from Illumina. In addition to a technology license in newborn screening that does not include sequencing, Baebies also received equipment, contracts, and other consideration in exchange for a share of ownership in the new company. The company was founded in 2013 and is based in Durham, North Carolina.

Hemex Health Logo
Hemex Health

Hemex creates affordable, life-changing medical diagnostics for under-served people everywhere. Its diagnostic platform is designed to reach populations at risk for malaria and sickle cell disease.

Truvian Sciences Logo
Truvian Sciences

Truvian Sciences is a healthcare company at the intersection of diagnostics and consumer technology. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. Powered by patented technologies and intelligent integration, Truvian's system delivers an alternative to off-site labs, providing immediate insights to inform healthcare decisions.

Genalyte Logo
Genalyte

Genalyte transforms the doctor-patient relationship by providing rapid diagnostic testing right in the doctor's office. The company's technology delivers results to physicians in minutes from just a single drop of blood, yielding better outcomes for the patient, empowering doctors to be more effective, and creating a more efficient healthcare system.

Visby Medical Logo
Visby Medical

Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The company’s technology development program culminated in an instrument-free, single-use PCR platform that rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. Visby Medical technology also offers the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. It was founded in 2015 and is based in San Jose, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.